Amgen Discloses FDA Paused Study of Early-Stage Obesity Drug
Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack.
Yahoo Finance17d
Amgen: Q4 Earnings Snapshot
THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Amgen Inc. (AMGN) on Tuesday reported fourth-quarter profit of $627 million. The Thousand Oaks, California-based company said it had ...